[Fusion proteins between PML and alpha-RAR in acute promyelocytic leukemia]. 1991

P Kastner, and A Perez, and Y Lutz, and C Rochette-Egly, and M P Gaub, and P Chambon
Laboratoire de Génétique Moléculaire des Eucaryotes du CNRS, U/184 de Biologie Moléculaire et de Génie Génétique de l'INSERM, Faculté de Médecine, Strasbourg, France.

Acute promyelotic leukemia is characterized by a t(15;17) chromosomal translocation which results in fusion products between PML (chromosome 15) and RAR-alpha (chromosome 17). We describe 2 classes of patients which possess different PMLRAR and RARPML fusion transcripts. We then discuss the functional properties of PML and show that PMLRAR can interfere with both PML and RAR-alpha functions.

UI MeSH Term Description Entries
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014212 Tretinoin An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE). Retinoic Acid,Vitamin A Acid,Retin-A,Tretinoin Potassium Salt,Tretinoin Sodium Salt,Tretinoin Zinc Salt,Vesanoid,all-trans-Retinoic Acid,beta-all-trans-Retinoic Acid,trans-Retinoic Acid,Acid, Retinoic,Acid, Vitamin A,Acid, all-trans-Retinoic,Acid, beta-all-trans-Retinoic,Acid, trans-Retinoic,Potassium Salt, Tretinoin,Retin A,Salt, Tretinoin Potassium,Salt, Tretinoin Sodium,Salt, Tretinoin Zinc,Sodium Salt, Tretinoin,Zinc Salt, Tretinoin,all trans Retinoic Acid,beta all trans Retinoic Acid,trans Retinoic Acid
D015473 Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION. Leukemia, Myeloid, Acute, M3,Leukemia, Progranulocytic,Myeloid Leukemia, Acute, M3,Progranulocytic Leukemia,Promyelocytic Leukemia, Acute,AML M3,Acute Promyelocytic Leukemia,Leukemia, Acute Promyelocytic,M3 ANLL,ANLL, M3,Acute Promyelocytic Leukemias
D015513 Oncogene Proteins Proteins coded by oncogenes. They include proteins resulting from the fusion of an oncogene and another gene (ONCOGENE PROTEINS, FUSION). Oncogene Products,Oncoprotein,Oncoproteins,Oncogene Product,Oncogene Protein,Product, Oncogene,Products, Oncogene,Protein, Oncogene,Proteins, Oncogene

Related Publications

P Kastner, and A Perez, and Y Lutz, and C Rochette-Egly, and M P Gaub, and P Chambon
June 1992, Proceedings of the National Academy of Sciences of the United States of America,
P Kastner, and A Perez, and Y Lutz, and C Rochette-Egly, and M P Gaub, and P Chambon
September 2010, Leukemia research,
P Kastner, and A Perez, and Y Lutz, and C Rochette-Egly, and M P Gaub, and P Chambon
December 2000, Blood,
P Kastner, and A Perez, and Y Lutz, and C Rochette-Egly, and M P Gaub, and P Chambon
January 2000, Acta haematologica,
P Kastner, and A Perez, and Y Lutz, and C Rochette-Egly, and M P Gaub, and P Chambon
January 1995, Haematologica,
P Kastner, and A Perez, and Y Lutz, and C Rochette-Egly, and M P Gaub, and P Chambon
March 1993, Blood,
P Kastner, and A Perez, and Y Lutz, and C Rochette-Egly, and M P Gaub, and P Chambon
August 1997, Molecular and cellular biology,
P Kastner, and A Perez, and Y Lutz, and C Rochette-Egly, and M P Gaub, and P Chambon
November 2010, Cancer research,
P Kastner, and A Perez, and Y Lutz, and C Rochette-Egly, and M P Gaub, and P Chambon
April 1993, Zhonghua yi xue za zhi,
P Kastner, and A Perez, and Y Lutz, and C Rochette-Egly, and M P Gaub, and P Chambon
March 2000, Medicina clinica,
Copied contents to your clipboard!